ArticleFrontiers in cardiovascular medicine2026
Association of sST2 with liver function in patients with acute heart failure related hospitalization.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the association between serum soluble ST2 (sST2) and liver injury biomarkers in patients with acute heart failure (AHF), and to evaluate the potential value of sST2 in identifying liver injury in AHF. Methods: A total of 134 patients with AHF (with or without liver injury) were prospectively enrolled, along with 187 age- and sex-matched healthy controls. Serum sST2 were measured within 24 h of hospital admission, along with comprehensive clinical and laboratory assessments. Univariate and multivariate linear regression analyses were performed to explore the relationships between sST2 and liver function parameters. ROC curve analysis was used to evaluate the discriminative ability of sST2 for liver injury. Results: Univariate analysis showed that sST2 had weak but statistically significant correlations with NT-proBNP ( Conclusion: Serum sST2 is strongly associated with liver injury markers, particularly AST and DBIL, in patients with AHF. Elevated sST2 is associated with underlying hepatic dysfunction and may serve as a potential biomarker linking cardiac decompensation and liver impairment. Although sST2 alone has limited sensitivity for liver injury, a combined panel of sST2, AST, and DBIL provides excellent diagnostic performance. This combined approach may serve as a useful tool for risk stratification and early identification of cardiogenic liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.